Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture.

Park JH, Kang KC, Shin DE, Koh YG, Son JS, Kim BH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA14 Aug 2013Cited by 29 (Europe PMC)

PMID23943161DOI10.1007/s00198-013-2458-7PepBankPUB-23943161

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In women with vertebral compression fracture, teriparatide was linked to less collapse progression than antiresorptive treatment, although both groups progressed.
In plain wordsIn women with vertebral fracture, teriparatide was linked to less collapse progression than antiresorptive treatment, although both groups progressed.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral collapse progression
Study
n = 68
Comparator
antiresorptive treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · minimum 3 monthsAs given in this study (human).
Source sentences
Summary
The progression of fractured vertebral body collapse was shown in both groups, but the degree of progression was significantly lower in group I than in group II.
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II).
Report a problemFND-2394316101
02HumanObservational studyEfficacy outcome
In women with vertebral fracture, teriparatide was linked to a smaller kyphosis angle increment than antiresorptive treatment.
In plain wordsIn women with vertebral fracture, teriparatide was linked to a smaller kyphosis angle increase than antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseKyphosis angle increment
Study
n = 68
Comparator
antiresorptive treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · minimum 3 monthsAs given in this study (human).
Measurements
Mean kyphosis increment
4 degrees
teriparatide
Mean kyphosis increment
6.8 degrees
antiresorptive
Source sentences
Summary
At the last follow-up, mean increments of kyphosis and wedge angle were significantly lower in group I (4.0° ± 4.2° and 3.6° ± 3.6°) than in group II (6.8° ± 4.1° and 5.8° ± 3.5°) (p = 0.032 and p = 0.037).
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II).
Report a problemFND-2394316102
03HumanObservational studyEfficacy outcome
In women with vertebral fracture, teriparatide was linked to a smaller wedge angle increment than antiresorptive treatment.
In plain wordsIn women with vertebral fracture, teriparatide was linked to a smaller wedge angle increase than antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseWedge angle increment
Study
n = 68
Comparator
antiresorptive treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · minimum 3 monthsAs given in this study (human).
Measurements
Mean wedge angle increment
3.6 degrees
teriparatide
Mean wedge angle increment
5.8 degrees
antiresorptive
Source sentences
Summary
At the last follow-up, mean increments of kyphosis and wedge angle were significantly lower in group I (4.0° ± 4.2° and 3.6° ± 3.6°) than in group II (6.8° ± 4.1° and 5.8° ± 3.5°) (p = 0.032 and p = 0.037).
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II).
Report a problemFND-2394316103
04HumanObservational studyEfficacy outcome
In women with vertebral fracture, teriparatide was linked to less anterior border height loss than antiresorptive treatment.
In plain wordsIn women with vertebral fracture, teriparatide was linked to less anterior border height loss than antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAnterior border height decrement
Study
n = 68
Comparator
antiresorptive treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · minimum 3 monthsAs given in this study (human).
Measurements
Anterior height decrement
9.6%
teriparatide
Anterior height decrement
18.1%
antiresorptive
Source sentences
Summary
Decrement percentages of anterior and middle border height were significantly lower in group I (9.6 ± 10.3 and 7.4 ± 7.5 %) than in group II (18.1 ± 9.7 and 13.8 ± 12.2 %) (p = 0.001 and p = 0.025), but not in posterior height (p = 0.086).
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II).
Report a problemFND-2394316104
05HumanObservational studyEfficacy outcome
In women with vertebral fracture, teriparatide was linked to less middle border height loss than antiresorptive treatment.
In plain wordsIn women with vertebral fracture, teriparatide was linked to less middle border height loss than antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseMiddle border height decrement
Study
n = 68
Comparator
antiresorptive treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · minimum 3 monthsAs given in this study (human).
Measurements
Middle height decrement
7.4%
teriparatide
Middle height decrement
13.8%
antiresorptive
Source sentences
Summary
Decrement percentages of anterior and middle border height were significantly lower in group I (9.6 ± 10.3 and 7.4 ± 7.5 %) than in group II (18.1 ± 9.7 and 13.8 ± 12.2 %) (p = 0.001 and p = 0.025), but not in posterior height (p = 0.086).
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II).
Report a problemFND-2394316105
06HumanObservational studyEfficacy outcome
In women with vertebral fracture, posterior height loss did not differ significantly between teriparatide and antiresorptive treatment.
In plain wordsIn women with vertebral fracture, posterior height loss did not differ significantly between teriparatide and antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePosterior height decrement
Study
n = 68
Comparator
antiresorptive treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · minimum 3 monthsAs given in this study (human).
Source sentences
Summary
Decrement percentages of anterior and middle border height were significantly lower in group I (9.6 ± 10.3 and 7.4 ± 7.5 %) than in group II (18.1 ± 9.7 and 13.8 ± 12.2 %) (p = 0.001 and p = 0.025), but not in posterior height (p = 0.086).
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II).
Report a problemFND-2394316106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.